HSV for tumour lysis

To view some of the files in this section, you will require a version of Adobe Acrobat. This is free to download and is available on the Adobe Acrobat website.

To view the PowerPoint presentations you will require Microsoft PowerPoint. You can download the latest PowerPoint viewer free from the Microsoft website.

You are welcome to download, view and use many of the slides contained in these presentations, however the original presenter and IHMF^Ž must be suitably acknowledged for any use, for example in oral presentations or written material. Please also be aware that some slides contain graphs, illustrations or other content that may not be the copyright of the presenter or the IHMF^Ž and permission ot use such material will need to be obtained from the copyright owner prior to use. Some of the slide presentations from the 13th IHMF^Ž Annual Meeting are subject to 'restricted use' and the presentations to which this applies are labelled with the notice 'Restricted Use - please contact the presenter prior to any use of the content of this presentation'. These 'restricted use' presentations may only be viewed online or downloaded to view, and the original presenter must be contacted prior to any use.

If you are in any doubt about your use of this material, please contact the IHMF Secretariat.

HSV for tumour lysis

Presented by JM Markert
University of Alabama at Birmingham, Birmingham, AL, USA.

Genetically-engineered herpes simplex virus type 1 (HSV-1) shows promise as a novel treatment for the therapy of a variety of malignancies. Malignant gliomas are the most prevalent primary human brain tumours, and are almost uniformly fatal. Viruses that are deleted for the gamma134.5 gene are aneurovirulent, but maintain their ability to replicate in and destroy a variety of human tumours, including malignant glioma. Pre-clinical studies have demonstrated the safety and efficacy of gamma134.5 mutants for use in the treatment of brain tumours. Animals with intracranial gliomas that are treated with these viruses have increased survival over untreated animals, with some animals showing cures. As a result of its pre-clinical success, one mutant, G207, has been taken forward by our group into clinical trials. A Phase I study of this virus has demonstrated its safety at doses up to 3 × 109 pfu. A Phase Ib trial is currently in progress. Second- and third-generation viruses constructed in the laboratory may be more effective than G207 while maintaining safety. The use of oncolytic HSV in the treatment of other types of neoplasms is also under study in clinical trials. HSV-1 shows strong potential as a new treatment for a variety of malignancies.

View PowerPoint Slide Presentation
PowerPoint Slide Presentation

Download PowerPoint Slide Presentation
Please complete the questionnaire and press the start download button. Your responses will be used by the site maintainers only, to improve the site, and will not be distributed elsewhere. All responses are anonymous and you will not be contacted as a result of submitting the questionnaire.

1.	What is your interest in herpes?
	Physician Other healthcare professional (e.g. nurse, pharmacist, etc) Student in health-related field Person with a herpesvirus infection Friend/loved one of a person with a herpesvirus infection General interest

2.	If you are a 'health professional', please select the most appropriate description of yourself from each of the following two lists.
	What is your occupation? What is your speciality?

The IHMFŽ is a registered trademark of PAREXEL MMS

Last Updated : 08/04/2004 15:24:34